Cellectis stem cells today proudly announces the launch of the world’s very first human iPS cell-derived hepatocyte product

Cellectis stem cells, a Business Unit of Cellectis Group (Alternext: ALCLS), a premier provider of Stem cell derived products and technologies, today announces the launch of a human iPS derived hepatocyte product, hiPS-HEPTM.
 
The hiPS-HEPTM demonstrate high reproducibility, homogeneity and a long life span of stable CYP activity, making them the ideal platform for various in vitro applications including drug discovery, toxicity testing and vaccine development. The hiPS-HEP™ are human hepatocyte-like cells derived from human induced Pluripotent Stem (iPS) cells under strict quality controlled and ethically approved procedures.
 
"Due to their high relevance in various industrial applications it makes the hiPS-HEP™ a really promising system for research and development", said Johan Hyllner, CSO of Cellectis stem cells. "The pharmaceutical industry has a great need for better and more clinically relevant models early in the drug development process to predict hepatotoxicity, find new drug targets and develop new vaccines."
 
"This novel product is the fruition of Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It illustrates our ambitions and the momentum of our future development in this field." said André Choulika, Chairman and CEO of Cellectis.